biote Corp.

BTMD Nasdaq SEC CIK 1819253
Follow biote Corp. Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $43.3M −9.6% vs same quarter last year
Net income $407K −95% vs same quarter last year
EPS, diluted $0.01 −95.5% vs same quarter last year
Operating cash flow $3.7M −73.8% vs same quarter last year
Revenue by quarter
$49.8M
$49M
$48.9M
$48M
$46.4M
$44.9M
$44.2M
$43.3M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income6 fiscal years
  • Revenue
  • Net income
−$50M$0$50M$100M$150M$200MFY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$192.2M$27M
FY24$197.2M$3.2M
FY23$185.4M$3.3M
FY22$165M−$969K
FY21$139.4M$11.1M
FY20--
MarginsShare of revenue
  • Operating margin
  • Net margin
−40%−20%0%20%40%FY20FY21FY22FY23FY24FY25
Show the numbers
YearOperating marginNet margin
FY2518.5%14.1%
FY2416%1.6%
FY2315.5%1.8%
FY22−36.8%−0.6%
FY2124.8%8%
FY20--
Free cash flowOperating cash flow minus capital expenditure
−$20M$0$20M$40MFY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25$30.2M
FY24$38.8M
FY23$26.5M
FY22−$9.5M
FY21$32.3M
FY20-
Returned to shareholdersDividends paid and shares bought back
  • Dividends
  • Buybacks
$0$5M$10M$15MFY20FY21FY22FY23FY24FY25
Show the numbers
YearDividendsBuybacks
FY25$1.7M$3.4M
FY24$4.7M$5.6M
FY23$8.7M-
FY22$12.9M-
FY21$11.4M-
FY20--
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • biote Corp.
  • Healthcare median
−100%−75%−50%−25%0%25%FY20FY21FY22FY23FY24FY25
Show the numbers
Yearbiote Corp.Healthcare median
FY2514.1%−30.6%
FY241.6%−47%
FY231.8%−58%
FY22−0.6%−80.4%
FY218%−71.8%
FY20-−62.2%